Long-term Prospective Study of Korean CADASIL Patients

Plain-language summary

This is a prospective observational study that follows Korean patients with CADASIL, a hereditary brain blood-vessel disease, over a long period. Patients aged 19 and older with suspected or genetically confirmed CADASIL (NOTCH3 mutation) who can provide written consent can take part. It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Jeju National University Hospital

Start date

7/10/2023

Estimated completion

12/31/2040

Countries

South Korea

Related genes

Locations

• Jeju City, South Korea

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age ≥ 19 years
* CADASIL suspected or confirmed by genetic testing (NOTCH3 mutation)
* Able to provide written informed consent (participant or legally authorized representative)

Exclusion Criteria:

* Contraindication to MRI (claustrophobia, metal implants, pacemaker)
* Acute ischemic or hemorrhagic stroke within 180 days prior to enrollment